Search research articles
Contact Us
Filters
Showing results (1-10 of 56) with videos related to
Page
of 6
Sort By:
Mediterranean Journal of Hematology and Infectious Diseases
|
September 13, 2017
Non-Secretory Myeloma: Ready for a new Definition?
Alessandro Corso, Silvia Mangiacavalli
Haematologica
|
March 1, 2002
Advantages of using thalidomide for the management of refractory myeloma patients
Alessandro Corso, Angela Lorenzi, Ester Orlandi, et al.
Leukemia Research
|
August 14, 2009
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients
Alessandro Corso, Silvia Mangiacavalli, Marzia Varettoni, et al.
American Journal of Hematology
|
December 11, 2012
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
Silvia Mangiacavalli, Lara Pochintesta, Cristiana Pascutto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 14, 2025
Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status
Roberto Mina, Silvia Mangiacavalli, Bernardo Rossini, et al.
Leukemia & Lymphoma
|
January 21, 2016
Implemented myeloma management with whole-body low-dose CT scan: a real life experience
Silvia Mangiacavalli, Sara Pezzatti, Fausto Rossini, et al.
Cancer
|
April 19, 2007
Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years
Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, et al.
Medicine
|
July 10, 2010
Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients
Marzia Varettoni, Alessandro Corso, Federica Cocito, et al.
European Journal of Haematology
|
June 13, 2009
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
Alessandro Corso, Marzia Varettoni, Silvia Mangiacavalli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 13, 2006
Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience
Patrizia Zappasodi, Alessandro Corso, Catherine Klersy, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 56) with videos related to
Sort By:
Page
of 6
Mediterranean Journal of Hematology and Infectious Diseases
|
September 13, 2017
Non-Secretory Myeloma: Ready for a new Definition?
Alessandro Corso, Silvia Mangiacavalli
Haematologica
|
March 1, 2002
Advantages of using thalidomide for the management of refractory myeloma patients
Alessandro Corso, Angela Lorenzi, Ester Orlandi, et al.
Leukemia Research
|
August 14, 2009
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients
Alessandro Corso, Silvia Mangiacavalli, Marzia Varettoni, et al.
American Journal of Hematology
|
December 11, 2012
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
Silvia Mangiacavalli, Lara Pochintesta, Cristiana Pascutto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 14, 2025
Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status
Roberto Mina, Silvia Mangiacavalli, Bernardo Rossini, et al.
Leukemia & Lymphoma
|
January 21, 2016
Implemented myeloma management with whole-body low-dose CT scan: a real life experience
Silvia Mangiacavalli, Sara Pezzatti, Fausto Rossini, et al.
Cancer
|
April 19, 2007
Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years
Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, et al.
Medicine
|
July 10, 2010
Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients
Marzia Varettoni, Alessandro Corso, Federica Cocito, et al.
European Journal of Haematology
|
June 13, 2009
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
Alessandro Corso, Marzia Varettoni, Silvia Mangiacavalli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 13, 2006
Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience
Patrizia Zappasodi, Alessandro Corso, Catherine Klersy, et al.
Page
of 6